Opioid switching to methadone: A pharmacoepidemiological study from a national prescription database

Palliative Medicine

Volumn 26, Issue 6, 2012, Pages 804-812

  Fredheim, Olav Magnus S ^a,b   Moksnes, Kristin ^b   Borchgrevink, Petter C ^a,b   Skurtveit, Svetlana ^c,d  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^c NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

Author keywords

Methadone; pain; palliative care; pharmacoepidemiological

Indexed keywords

BUPRENORPHINE; FENTANYL; HYDROMORPHONE; KETOBEMIDONE; METHADONE; MORPHINE; OPIATE; OXYCODONE; PETHIDINE;

ADULT; ANALGESIA; ARTICLE; CANCER PAIN; CANCER PATIENT; CHRONIC PAIN; DATA BASE; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EPIDEMIOLOGICAL DATA; FEMALE; FOLLOW UP; HUMAN; LONG TERM CARE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NORWAY; PALLIATIVE THERAPY; PHARMACOEPIDEMIOLOGY; PRESCRIPTION; PREVALENCE; RISK ASSESSMENT;

ADULT; AGED; ANALGESICS, OPIOID; DATABASES, FACTUAL; DRUG PRESCRIPTIONS; DRUG SUBSTITUTION; HUMANS; MALE; METHADONE; MIDDLE AGED; NORWAY; OPIATE SUBSTITUTION TREATMENT; PAIN; PHARMACOEPIDEMIOLOGY;

EID: 84865490338     PISSN: 02692163     EISSN: 1477030X     Source Type: Journal    
DOI: 10.1177/0269216311412415     Document Type: Article

References (25)

1. Fredheim OM, Moksnes K, Borchgrevink PC, Kaasa S, Dale O. Clinical pharmacology of methadone for pain. Acta Anaesthesiol Scand. 2008 ; 52: 879-889
2. QuigleyC. Opioid switching to improve pain relief and drug tolerability. Cochrane Database Syst Rev2004; 3: CD004847. DOI: 10.1002/14651858.CD00484710. 1002/14651858.CD004847.
3. Parsons HA, De la Cruz M, El Osta B, et al. Methadone initiation and rotation in the outpatient setting for patients with cancer pain. Cancer. 2010 ; 116: 520-528
4. Fredheim OM, Kaasa S, Dale O, Klepstad P, Landro NI, Borchgrevink PC. Opioid switching from oral slow release morphine to oral methadone may improve pain control in chronic non-malignant pain: a nine-month follow-up study. Palliat Med. 2006 ; 20: 35-41
5. Moulin DE, Palma D, Watling C, Schulz V. Methadone in the management of intractable neuropathic noncancer pain. Can J Neurol Sci. 2005 ; 32: 340-343
6. Ettinger DS, Vitale PJ, Trump DL. Important clinical pharmacologic considerations in the use of methadone in cancer patients. Cancer Treat Rep. 1979 ; 63: 457-459
7. Hernansanz S, Gutierrez C, Rubiales AS, Flores LA, del Valle ML. Opioid rotation to methadone at home. J Pain Symptom Manage. 2006 ; 31: 2-4
8. Hunt G, Bruera E. Respiratory depression in a patient receiving oral methadone for cancer pain. J Pain Symptom Manage. 1995 ; 10: 401-404
9. Watanabe S, Tarumi Y, Oneschuk D, Lawlor P. Opioid rotation to methadone: proceed with caution. J Clin Oncol. 2002 ; 20: 2409-2410
10. WHO Collaborating Centre for Drug Statistics Methodology. ATC classification index with DDDs Oslo; 2009. Available from: http://www.whocc.no (accessed 15 October 2010).
11. Gardner-Nix JS. Oral methadone for managing chronic nonmalignant pain. J Pain Symptom Manage. 1996 ; 11: 321-328
12. Gil M, Sala M, Anguera I, et al. QT prolongation and Torsades de Pointes in patients infected with human immunodeficiency virus and treated with methadone. Am J Cardiol. 2003 ; 92: 995-997
13. Hays H. High dosing methadone and a possible relationship to serious cardiac arrhythmias. Pain Res Manag. 2001 ; 6: 64
14. Krantz MJ, Lewkowiez L, Hays H, Woodroffe MA, Robertson AD, Mehler PS. Torsade de pointes associated with very-high-dose methadone. Ann Intern Med. 2002 ; 137: 501-504
15. Walker PW, Klein D, Kasza L. High dose methadone and ventricular arrhythmias: a report of three cases. Pain. 2003 ; 103: 321-324
16. Wilcock A, Beattie JM. Prolonged QT interval and methadone: implications for palliative care. Curr Opin Support Palliat Care. 2009 ; 3: 252-257
17. Quang-Cantagrel ND, Wallace MS, Magnuson SK. Opioid substitution to improve the effectiveness of chronic noncancer pain control: a chart review. Anesth Analg. 2000 ; 90: 933-937
18. Riley J, Ross JR, Rutter D, et al. No pain relief from morphine? Individual variation in sensitivity to morphine and the need to switch to an alternative opioid in cancer patients. Support Care Cancer. 2006 ; 14: 56-64
19. Fisher K, Stiles C, Hagen NA. Characterization of the early pharmacodynamic profile of oral methadone for cancer-related breakthrough pain: a pilot study. J Pain Symptom Manage. 2004 ; 28: 619-625
20. Hagen NA, Moulin DE, Brasher PM, et al. A formal feasibility study of sublingual methadone for breakthrough cancer pain. Palliat Med. 2010 ; 24: 696-706
21. Hagen NA, Fisher K, Stiles C. Sublingual methadone for the management of cancer-related breakthrough pain: a pilot study. J Palliat Med. 2007 ; 10: 331-337
22. Breivik H, Cherny N, Collett B, et al. Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes. Ann Oncol. 2009 ; 20: 1420-1433
23. Mercadante S, Zagonel V, Breda E, et al. Breakthrough pain in oncology: a longitudinal study. J Pain Symptom Manage. 2010 ; 40: 183-190
24. Patt RB, Ellison NM. Breakthrough pain in cancer patients: characteristics, prevalence, and treatment. Oncology. 1998 ; 12: 1035-1046
25. Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain. 1990 ; 41: 273-281